Tailored Elastin-like Recombinamers as Advanced Systems for Cell Therapies in Diabetes Mellitus:a Synthetic Biology Approach towards a Bioeffective and Immunoisolated Biosimilar Islet/Cell Niche
tipo de financiamento European Comission
programa H2020-NMP-2014-two-stage
acrónimo/
referência
ELASTISLET
referência alternative 646075
grupo(s) de investigação 5 - materiais biomédicos e biomiméticos;
departamento Chemistry (DQ)
período de execução 2016-06-15 - 2019-05-31 ( 36 Meses )
resumo/
palavras-chave

ELASTISLET aims to create a breakthrough development in encapsulation technology and its use in cell and tissue therapies for the treatment of type 1 and 2 diabetes. ELASTISLET will combine leading technologies in biomaterial design, production and processing, cross-linking/grafting technology and cell therapy, to synergistically integrate them into a new immune-isolation and biomimetic scaffolding approach for islet and cell transplantation in diabetes treatment. ELASTISLET’s starting point is a highly innovative and versatile family of superior biomaterials, the Elastin-like Recombinamers (ELRs). Those innovative materials will be combined with the most cutting-edge encapsulation technologies, such as reactive LbL. ELASTISLET relies on the most innovative ideas taken from synthetic biology, nanobiotechnology and molecular and cellular biology to build the ideal niche for islet/cell encapsulation and transplantation.
ELASTISLET main objective is to achieve a functional coating that fulfils, first, the basic requirements of optimal biocompatibility and physical properties (permselectivity) but, second, generate a capsule that can promote an intense and directed cross talk through all cell-material interfaces involved: the implant-surrounding tissue (outer) interface and cargo cells-capsule (inner) interface. At the end, a capsule that is able not only to cloak its content and isolate it from the immune rejection but that it is able to biologically interact with the surrounding tissues and its cargo simultaneously in a way that the implanted capsule will immediately interact and fuse with the surrounding tissues creating a real continuity of the extracellular matrix from the core of the capsule to the surrounding hosts tissues and procuring adequate nutrient supply. That will provide a physiologically ideal biomimetic environment for the implanted islets/cells to survive and function in the long term without perceiving a foreign, unusual or hostile environment.

coordenador
/ip local
João Mano
ciceco status Parceiro
instituição proponente UNIVERSIDAD DE VALLADOLID
instituições participante(s)

UNIVERSIDADE DO MINHO
Portugal
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
MEDIZINISCHE UNIVERSITAET WIEN
Austria
UNIVERSITAET BASEL
Switzerland
Università degli Studi di Perugia
Italy
Promoscience srl
Italy
TECHNICAL PROTEINS NANOBIOTECHNOLOGY SL
Spain
AXIOGENESIS AG
Germany
ASPHALION SL
Spain
UPPSALA UNIVERSITET
Sweden
UNIVERSIDADE DE AVEIRO
Portugal

parceiro(s) internacional Sim
orçamento total 6.718.036€
orçamento ciceco 354.941€
centro de custos 3.89.232
link http://www.elastislet.eu/en/
publicações
Apoio

1suponsers_list_ciceco.jpg